RxDoctor Payments Data

David Weaver, MD

Interventional Cardiology · Wilmington, NCNPI 1609836279

Payments from drug & device makers

$8,061in general payments, 2019–2025

Across 147 payments — averaging $54.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$3K
  • Medtronic$1K
  • Inari Medical, Inc.$1K
  • Boston Scientific$559
  • Abbott$426
  • Cordis US CORP.$240
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$3,37842%
  • Food & beverage$4,68358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,061 in reported general payments places this provider in the 45th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$271,583
Medicare patients
1,070
Services billed
3,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$152,665
Repatha SureclickEvolocumab82$105,436
XareltoRivaroxaban26$32,634
FarxigaDapagliflozin Propanediol19$17,845
EntrestoSacubitril/Valsartan16$13,312
Praluent PenAlirocumab16$9,568
Metoprolol Succinate818$9,163
Ranolazine ErRanolazine28$3,448
Atorvastatin Calcium303$3,243
Olmesartan Medoxomil227$3,188
ClopidogrelClopidogrel Bisulfate251$2,489
Droxidopa12$2,048
Torsemide115$1,955
Losartan Potassium173$1,927
Spironolactone-HctzSpironolact/Hydrochlorothiazid28$1,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$152,665164 claims
Johnson & JohnsonXarelto$16$32,63426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →